E
Exiqon
Supplier of flexible solutions for RNA research
About Exiqon
Exiqon specializes in providing advanced RNA research tools and services, catering to researchers and pharmaceutical companies. Operating in the biotechnology market, Exiqon offers a range of products and services such as RNA isolation, sequencing, quantitative real-time PCR (qPCR), microarray analysis, and in situ hybridization. The company's business model revolves around selling these specialized tools and offering custom services to meet the unique needs of their clients. Revenue is generated through the sale of products and the provision of custom research services. Exiqon's clients primarily include academic researchers, biotech firms, and pharmaceutical companies looking for reliable and specific RNA analysis solutions.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1995
- Headquarters
- Vedbæk, Denmark
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 30.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Supply Chain Management, Biotechnology, Genetics and genomics, Health Diagnostics, RNA, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Mar 2016 | $100M | $100M | Qiagen | — |
| IPO✓Exit | Jun 2007 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Exiqon is 30 monthly website visits, down 50% over the last three months. Exiqon's team declined 82.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Danske Bank
SLS Venture
LD Pensions
BioFund Management
Teknoinvest
Other known investors1 additional known investor
Qiagen
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Exiqon on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Exiqon’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.